Niagen Bioscience (NAGE) Stock Insights

NAGE price $2.54 +0.04 +1.60%

Ticker
NAGE
Price
$2.54
Change
+0.04 +1.60%
Market cap ?
$200.98M
Beta ?
2.02
Sector
Healthcare
Industry
Biotechnology

Fair value

NAGE fair value $3.26. Price $2.54. Price is 22% below fair value.

Below fair value, and cheaper than usual. A larger discount than on 98% of days in the past 5 years.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Calculated with a 10-year free-cash-flow discount. Starting free cash flow 10.69M. Growth 11.06%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 12.00% (beta 2.0). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 79.13M. Net debt -61.97M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the median P/E of the company's industry. That median uses listed stocks worth at least $10 billion with a positive P/E of 100 or below, and the industry needs at least eight of them. Otherwise the sector median is used when that group also has at least eight, then the market median of those large companies. The multiple used is the lower of that median and 1.25 times the stock's own 10-year median P/E, then kept between 8 and 30. If the stock has no 10-year median, the peer median is kept between 8 and 30. Fair value is the average of the cash-flow value and the earnings value when both exist. Card and credit companies use the earnings value only, because changes in customer receivables distort free cash flow. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.

Compare NAGE

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-04—-0.01—33.71M
2026-08-040.010.0129.79M30.53M
2026-05-060.070.0631.47M31.03M
2026-03-040.030.0233.84M31.70M
2025-11-040.050.0133.99M31.10M
2025-08-060.040.0231.12M28.31M
2025-05-070.040.0230.48M27.07M
2025-03-040.090.0229.12M26.77M
2024-10-310.030.0125.58M24.03M
2024-08-07-0.00-0.0222.74M23.32M
2024-05-08-0.01-0.0222.15M23.48M
2024-03-060.00-0.0321.20M20.81M
2023-11-080.00-0.0319.50M20.30M
2023-08-09-0.03-0.0420.32M19.42M
2023-05-10-0.03-0.0522.56M19.41M
2019-12-31-0.15—13.09M—
2019-09-30-0.12—12.05M—
2019-06-30-0.14—11.10M—
2019-03-31-0.15—10.05M—
2018-12-31-0.15—9.07M—
2018-09-30-0.16—8.12M—
2018-06-30-0.15—7.80M—
2018-03-31-0.15—6.57M—
2017-12-31-0.17—7.53M—
2017-09-300.04—6.08M—
2017-06-30-0.07—4.22M—
2017-03-31-0.05—3.37M—
2016-12-31-0.06—5.64M—
2016-09-30-0.03—3.94M—
2016-06-30-0.00—8.83M—
2016-03-310.01—7.33M—
2015-12-31-0.02—17.88M—
2015-09-30-0.00—6.29M—
2015-06-30-0.01—6.10M—
2015-03-31-0.03—5.26M—
2014-12-31-0.04—15.31M—
2014-09-30-0.02—4.14M—
2014-06-30-0.05—3.86M—
2014-03-31-0.05—3.07M—
2013-12-31-0.03—10.16M—

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-06-30Lopez Carlos LuisBuy2.31K$2.716.27K
2026-06-30Pamir OzanBuy4.25K$2.7111.53K
2026-06-30Fried Robert NBuy1.11K$2.713.00K
2026-06-24YU Wing Tak WendyBuy31.75K$3.45109.52K
2026-06-24Ng Wang Yu GaryBuy31.75K$3.45109.52K
2026-06-24Cohen AnnBuy31.75K$3.45109.52K
2026-06-24Patrick KristinBuy31.75K$3.45109.52K
2026-06-24Shahbazi HamedBuy31.75K$3.45109.52K
2026-06-24Rubin Steven DBuy31.75K$3.45109.52K
2026-06-24Jaksch Frank L JrBuy31.75K$3.45109.52K
2026-04-24Fried Robert NBuy20.00K$2.6152.20K
2026-04-24Fried Robert NSell20.00K$2.6152.20K
2026-02-19Lopez Carlos LuisBuy41.42K$4.94204.61K
2026-02-19Pamir OzanBuy62.13K$4.94306.93K
2026-02-19Fried Robert NBuy503.94K$4.942.49M
2025-11-14Pamir OzanBuy4.46K$6.8130.41K
2025-11-14Pamir OzanBuy2.22K$6.8515.21K
2025-06-24Shahbazi HamedBuy20.00K$14.13282.60K
2025-06-24YU Wing Tak WendyBuy20.00K$14.13282.60K
2025-06-24Patrick KristinBuy20.00K$14.13282.60K
2025-06-24Rubin Steven DBuy20.00K$14.13282.60K
2025-06-24Ng Wang Yu GaryBuy20.00K$14.13282.60K
2025-06-24Cohen AnnBuy20.00K$14.13282.60K
2025-06-24Jaksch Frank L JrBuy20.00K$14.13282.60K
2025-04-09Fried Robert NBuy66.67K$3.30220.00K
2025-04-09Fried Robert NSell66.67K$3.30220.00K

Institutional holders

HolderSharesChangeChange %Value
No data yet.

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Niagen Bioscience (NAGE) Stock Insights

NAGE$2.54+0.04 +1.60%

$200.98M

Market Cap

—

P/E

—

Forward P/E

—

Score

Price History